Laboratory for Advanced Medicine & Health Group (LAMH) is an AI-driven cancer screening and early diagnosis innovation company founded by international business leaders, top scientists and authoritative doctors with the concept of "making cancer screening more accurate, earlier and easier". LAMH was founded by international business leaders, top scientists and authoritative doctors with the concept of "making cancer screening more accurate, earlier and easier", and has raised over RMB 1 billion since its inception. As a global leader in early screening and diagnosis of cancer, LAMH has collaborated with many top cancer centers, universities and their affiliated hospitals, published relevant research results in top international journals such as Nature, Science, Cell and its sub-journals, PNAS, and established a full product pipeline for early screening and diagnosis of liver cancer, intestinal cancer, lung cancer and pan-cancer. LAMH is committed to providing a full lifecycle service with the help of AI-driven technology, combined with genomics and clinical medicine theories.

LAMH, an independent entity in China, is headquartered in the central business district of Pazhou, Guangzhou, with a R&D and registration center in Beijing Economic and Technological Development Zone, and a Southern and Northern Medical Laboratory (ICL) meeting PCR and NGS standards in Guangzhou Biological Island and Beijing Yizhuang, respectively. There is an IVD GMP factory in Guangzhou Science City that has passed the NMPA system assessment,Helio Genomics is a U.S. independent entity headquartered in Irvine, California, with CLIA - and CAP-certified central laboratories in Indiana.